Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor - Optimize Trial
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3119 participants.
Also called NCT01113372
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose supportive care
- Phase
- Phase 4
- Enrolled
- 3,119 participants
- Sponsor
- Registry
-
NCT01113372
-
- Other papers using this trial's data
- Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Brazil
- Registry status
- Completed
Technical summary
Registry record NCT01113372. Randomized; single masking; primary purpose supportive care. Start 2010-04 (registry gives no type); primary completion 2013-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor - Optimize Trial
- Acronym
- OPTIMIZE
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Clopidogrel
- Lead sponsor
- Cardiovascular Research Center, Brazil
- Collaborator
- Medtronic
Record details
- Record id
cardio:ct-nct01113372- Content hash
a46fdf7b4f261c2e1b23eeb0a13593402153ca60f5d7e08515a3e947396d68a4